UNSPSC 51182076: Testosterone undecanoate

This classification denotes a therapeutic testosterone with the molecular formula C30H48O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H16A5VCT9C, chemically known as 5-alpha-androstan-3-one, 17-beta-hydroxy-, undecanoate but more generally known as testosterone undecanoate, which bears US NIH Compound Identifier 65157. European Medicines Agency schedules Testosterone undecanoate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04744MIG.

UNSPSC 51182076 Testosterone undecanoate (Commodity) covers pharmaceutical-grade testosterone undecanoate products supplied to state and local government healthcare facilities, school districts, and other public entities through cooperative purchasing agreements and direct procurement. State and local governments buy this product primarily as part of broader generic pharmaceutical procurement vehicles that consolidate purchasing across multiple jurisdictions and agencies; the product appears in mixed multi-source pharmaceutical RFPs where it competes for volume alongside other generic drugs rather than as a standalone line item. Issuing bodies include state pharmacy benefit programs, state departments of health and human services, cooperative purchasing alliances, county health departments, and institutional healthcare purchasers within state and local systems. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, is a standout repeat buyer operating a consolidated purchasing vehicle that draws participation from multiple states and local entities.

MMCAP's recent RFP (S1070000015802, posted January 20, 2026, due March 26, 2026) establishes multiple-award contracts for generic multi-source pharmaceuticals and OTC products effective July 1, 2026, with testosterone undecanoate among the NDC-specified product list. Vendors must supply through authorized wholesalers (AmerisourceBergen/Cencara, Cardinal Health, and Morris & Dickson), maintain cGMP and DSCSA compliance, carry $5 million commercial general liability insurance, and accept a 3 percent administrative fee on all purchases. The contract term runs two years for new vendors with optional MMCAP extensions; incumbent vendors' amendments extend through June 30, 2028. All products must be available by May 15, 2026, with expiration dates at least one year from manufacture. Pricing is weighted at 75 percent of the evaluation; proposers must submit detailed product and NDC data in CSV format through ePro by March 26, 2026, with a February 18, 2026 cutoff for questions. The RFP contains no disclosed award value or budget range and applies no set-aside designations based on available documentation.